logo
  

Pre-market Movers: REV, ASTL, VNRX, VORB, GGR…

us pre market 053119 15jun22 lt

The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 06.40 A.M. ET).

In the Green

Revlon, Inc. (REV) is up over 21% at $2.27
Algoma Steel Group Inc. (ASTL) is up over 15% at $9.14
VolitionRx Limited (VNRX) is up over 15% at $2.27
Virgin Orbit Holdings, Inc. (VORB) is up over 14% at $2.98
Gogoro Inc. (GGR) is up over 13% at $5.19
Dune Acquisition Corporation (DUNE) is up over 11% at $11.11
374Water Inc. Common Stock (SCWO) is up over 11% at $3.57
New Oriental Education & Technology Group Inc. (EDU) is up over 8% at $23.04
ReneSola Ltd (SOL) is up over 8% at $4.80
Endeavour Silver Corp. (EXK) is up over 8% at $3.70
Invitae Corporation (NVTA) is up over 7% at $2.38
Gaotu Techedu Inc. (GOTU) is up over 7% at $2.04
Incyte Corporation (INCY) is up over 6% at $70.80

In the Red

Comera Life Sciences Holdings, Inc. (CMRA) is down over 13% at $2.29
Belite Bio, Inc (BLTE) is down over 11% at $24.95
Symbotic Inc. (SYM) is down over 11% at $13.92
IronNet, Inc. (IRNT) is down over 10% at $2.29
Planet Labs PBC (PL) is down over 8% at $4.69
MicroStrategy Incorporated (MSTR) is down over 7% at $145.50
Borr Drilling Limited (BORR) is down over 7% at $5.44
Tuya Inc. (TUYA) is down over 5% at $2.80

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT